Fluicell AB (publ) (STO:FLUI)
9.45
+0.45 (5.00%)
Feb 11, 2026, 3:45 PM CET
Fluicell AB Revenue
Fluicell AB had revenue of 3.51M SEK in the quarter ending September 30, 2025, with 578.53% growth. This brings the company's revenue in the last twelve months to 13.20M, up 748.46% year-over-year. In the year 2024, Fluicell AB had annual revenue of 5.35M with 60.25% growth.
Revenue (ttm)
13.20M
Revenue Growth
+748.46%
P/S Ratio
0.94
Revenue / Employee
1.20M
Employees
11
Market Cap
12.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.35M | 2.01M | 60.25% |
| Dec 31, 2023 | 3.34M | 87.00K | 2.68% |
| Dec 31, 2022 | 3.25M | 649.00K | 24.94% |
| Dec 31, 2021 | 2.60M | -2.03M | -43.86% |
| Dec 31, 2020 | 4.64M | 2.15M | 86.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 22.65M |
| AcouSort AB | 10.80M |
| NanoEcho AB | 3.43M |
| Aptahem AB | 2.47M |
| 2cureX AB | 1.98M |
| Lipigon Pharmaceuticals AB | 1.32M |
| Stayble Therapeutics AB | -340.00K |
| LIDDS AB | -911.00K |